Paul Kerr

Paul Kerr is an Honorary Professor at Queen's University Belfast, where he contributes to the university's academic community while also serving as the CEO of AilseVax, a biotechnology company focused on developing novel therapeutic vaccines for cancer patients. His work at AilseVax is significant in the field of immunotherapy, aiming to enhance the immune system's ability to recognize and combat cancer cells.12

Professional Background

• Education: Paul Kerr is an alumnus of Queen's University Belfast, which has informed much of his professional journey.
• Career: He has over 20 years of experience in the biotechnology sector, holding various roles that span different functions within the industry. Before his current role at AilseVax, he was involved with Fusion Antibodies, another biopharmaceutical company.23

Contributions and Achievements

• Under his leadership, AilseVax has gained recognition for its innovative approaches to cancer treatment, including securing £1.5 million in seed funding to advance its research initiatives.1
• Kerr has been instrumental in fostering collaborations between Queen's University and other institutions, enhancing research capabilities in cancer vaccine development.1

Current Role

As an Honorary Professor, Kerr engages with students and faculty at Queen's University Belfast, contributing to academic discussions and research initiatives while also guiding the next generation of scientists in the field of biotechnology.3